Hoth Therapeutics宣布 HT-001在治疗 EGFR抑制剂相关丘疹脓疱性发疹方面取得积极成果，研究结果将在 2025年美国皮肤病学会年会上公布-动脉网

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

CISION 等信源发布 2025-03-06 02:40



可切换为仅中文







The data will be presented at the

数据将在以下位置展示：

American Academy of Dermatology (AAD) 2025 Annual Meeting

美国皮肤病学会（AAD）2025年年会

, which takes place

，这一过程

March 7-11, 2025

2025年3月7日至11日

, highlighting

，突出显示

HT-001

as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities.

作为EGFR抑制剂诱导的皮肤毒性的潜在突破性疗法。

The recent case study will be highlighted that demonstrated the efficacy of

最近的案例研究将重点展示其有效性

HT-001 2% cream

HT-001 2%乳膏

in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab. The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors. After just one week of applying

在一名59岁正在接受紫杉醇、曲妥珠单抗和帕妥珠单抗治疗的转移性乳腺癌患者中。患者面部、头皮和上背部出现了瘙痒、灼热的红色丘疹，这是EGFR抑制剂已知的皮肤科副作用。仅在使用一周后就出现了症状。

HT-001 2% cream

HT-001 2%乳膏

twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks.

患者每天两次出现症状和病灶完全消退，且在接下来的三周内病灶未再复发。

NEW YORK

纽约

，

March 5, 2025

2025年3月5日

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:

/PRNewswire/ -- Hoth Therapeutics, Inc.（纳斯达克：

HOTH

霍斯

), a patient-focused biopharmaceutical company, is excited to announce promising findings for its novel therapeutic candidate,

)，一家以患者为中心的生物制药公司，兴奋地宣布其新型治疗候选药物取得了令人鼓舞的发现，

HT-001

, a topical neurokinin 1 receptor (NK1R) antagonist, in the treatment of Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions (EGFRi PPEs).

，一种局部神经激肽1受体（NK1R）拮抗剂，用于治疗表皮生长因子受体抑制剂相关的丘疹脓疱性皮疹（EGFRi PPEs）。

The data will be presented at the

数据将在以下位置展示：

American Academy of Dermatology (AAD) 2025 Annual Meeting

美国皮肤病学会（AAD）2025年年会

, which takes place

，发生

March 7-11, 2025

2025年3月7日至11日

, highlighting

，突出显示

HT-001

as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities.

作为EGFR抑制剂诱导的皮肤毒性的潜在突破性疗法。

A recent case study demonstrated the efficacy of

最近的一个案例研究证明了其有效性

HT-001 2% cream

HT-001 2%乳膏

在一名59岁正在接受紫杉醇、曲妥珠单抗和帕妥珠单抗治疗的转移性乳腺癌患者中。该患者面部、头皮和上背部出现了瘙痒、灼烧感的红色丘疹，这是EGFR抑制剂已知的皮肤科副作用。在仅使用一周后

HT-001 2% cream

HT-001 2%乳膏

twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks.

患者每天两次，症状和病灶完全消退，且在接下来的三周内病灶未再复发。

'These findings demonstrate the potential of

“这些发现展示了

HT-001

as a safe and effective therapy for EGFR inhibitor-associated skin toxicities,' said

作为一种安全有效的EGFR抑制剂相关皮肤毒性的治疗方法，'

Robb Knie

罗布·克尼

, CEO at Hoth Therapeutics. 'With a significant unmet need for long-term, well-tolerated treatment options,

，Hoth Therapeutics首席执行官。“对于长期、耐受性良好的治疗方案存在显著未满足的需求，

HT-001

could offer relief to cancer patients experiencing debilitating skin reactions.'

可以为经历着衰弱性皮肤反应的癌症患者提供缓解。

HT-001 works by blocking the pro-inflammatory effects of the

HT-001 通过阻断促炎作用来发挥作用

Substance P (SP)-NK1R

P物质（SP）-NK1R

pathway, a key mediator of neurogenic inflammation. Preclinical research has shown that

通路，是神经源性炎症的关键介质。临床前研究表明

HT-001

reduces inflammation and hair loss associated with EGFR inhibitor therapy. These latest clinical observations further support its potential role in dermatologic oncology.

减少与EGFR抑制剂治疗相关的炎症和脱发。这些最新的临床观察进一步支持了其在皮肤肿瘤学中的潜在作用。

Hoth Therapeutics is currently conducting a

Hoth Therapeutics目前正在开展一项

Phase 2A clinical trial

第2A阶段临床试验

to evaluate the efficacy and safety of

评估有效性和安全性

HT-001

in a broader patient population. The trial will assess the treatment's effectiveness across varying severities of

在更广泛的患者群体中。该试验将评估治疗在不同严重程度下的有效性。

EGFRi PPEs

EGFR抑制剂类药物相关性丘疹脓疱性病变

and explore its impact on other dermatologic manifestations induced by EGFR inhibitors.

并探讨其对EGFR抑制剂引起的其他皮肤表现的影响。

For more information about

更多信息，请参阅

HT-001

and ongoing clinical trials, visit

并持续进行的临床试验，请访问

www.hoththerapeutics.com

About Hoth Therapeutics, Inc.

关于霍斯治疗公司

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing.

Hoth Therapeutics是一家临床阶段的生物制药公司，致力于开发创新、有影响力和突破性的治疗方法，旨在改善患者的生活质量。我们是早期药物研发的催化剂，将药物从实验室提升到临床前和临床测试阶段。

Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit .

通过采用以患者为中心的方法，我们与科学家、临床医生和关键意见领袖团队合作，寻找并研究具有巨大潜力的治疗方法，以实现突破并多样化治疗选择。欲了解更多信息，请访问。

https://ir.hoththerapeutics.com/

。

Forward-Looking Statement

前瞻性声明

This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions.

本新闻稿包含基于 Hoth 当前预期的前瞻性陈述，这些陈述可能构成 1995 年《私人证券诉讼改革法案》及其他联邦证券法的安全港条款下的前瞻性陈述，并受重大风险、不确定性和假设的影响。

These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans.

这些声明涉及霍斯的业务战略；监管提交的时机；获得并维持现有产品候选物及我们可能开发的任何其他产品候选物的监管批准的能力，以及我们可能获得的任何批准下的标签；临床试验的时机和成本，以及其他费用的时机和成本；市场对我们产品的接受程度；当前冠状病毒大流行或任何其他健康流行病对我们业务、临床试验、研究计划、医疗系统或全球经济整体的最终影响；我们的知识产权；我们对第三方组织的依赖；我们的竞争地位；我们的行业环境；我们预期的财务和运营结果，包括预期的收入来源；我们关于可用市场规模、产品优势、产品定价和产品上市时间的假设；管理层对未来收购的期望；关于我们目标、意图、计划和期望的声明，包括新产品的引入和市场开拓；以及我们的现金需求和融资计划。

There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as 'could,' 'believe,' 'anticipate,' 'in.

有许多因素可能导致实际事件与这些前瞻性陈述所表明的情况有重大差异。你不应过分依赖这些包含诸如“可能”、“相信”、“预期”、“在”等词语的前瞻性陈述。

Investor Contact:

投资者联系方式：

LR Advisors LLC Email:

LR Advisors LLC 电子邮件：

investorrelations@hoththerapeutics.com

投资者关系@hoththerapeutics.com

www.hoththerapeutics.com

Phone: (678) 570-6791

电话：（678）570-6791

SOURCE Hoth Therapeutics, Inc.

来源：Hoth Therapeutics, Inc.